Tubular epithelial reflux in the kidney in aflatoxin poisoning.

T. Madhavan,K. Rao

DOI: https://doi.org/10.1002/PATH.1700930131

The Journal of Pathology and Bacteriology

Abstract:

What problem does this paper attempt to address?

Newborn Screening for Ornithine Transcarbamylase Deficiency in Zhejiang Province and the Follow-Up Analysis

周朵,杨茹莱,黄新文,童凡,黄晓磊,钱古柃,杨昕,杨建滨,赵正言

DOI: https://doi.org/10.3760/cma.j.cn101070-20221102-01246

2023-01-01

Abstract:Objective:To investigate the incidence, clinical characteristics and prognosis of ornithine transcarbamylase deficiency(OCTD) in newborns in Zhejiang Province.Methods:A retrospective research was conducted.A total of 4 261 036 newborns from Department of Genetics and Metabolism, Children′s Hospital, Zhejiang University School of Medicine, between January 2009 and December 2021 were screened for inherited metabolic disorders using tandem mass spectrometry.OCTD was confirmed by urine organic acid and OTC gene analysis.Patients with OTCD received guidance on diet and lifestyle management, and were treated with citrulline and arginine.Long-term follow-up was performed.Their growth and intellectual development were evaluated. Results:A total of 7 patients with OCTD were diagnosed, with an incidence of 1.6/1 million.All patients were males.Two patients had neonatal-onset OCTD, and the other 5 had late-onset OCTD.Symptoms occurred several times in 6 patients, inducing hyperammonemia and hepatic impairment.One patient had no clinical manifestation.One patient died in the neonatal period.Blood citrulline levels were decreased in 7 patients to varying degrees.Uracil levels were increased in 4 patients, and 1 of them was complicated with elevated orotic acid levels.All patients had hemizygote variations in the OTC gene, including 6 missense variations(c.604C>T, c.386G>A, c.779T>C, c.1019C>T, c.594C>G, c.931G>A) and 1 intron variation(c.514-35C>G). Two variants(c.594C>G, c.514-35C>G) were never reported previously. Conclusions:The OTCD incidence by newborn screening is low with 1.6/1 million in Zhejiang province.All patients are males and present hypocitrullinemia.The clinical manifestations of OTCD are highly heterogeneous.The neonatal-onset form is severe and survivors always suffer serious sequelae.The late-onset form is mostly manifested with hyperammonemia and hepatic impairment.There may be association between phenotype and genotype.Two novel OTC variants are identified, which further expands the mutational spectrum.
Perinatal management and follow-up in a child with a prenatal diagnosis of OTC deficiency: a case report

Álvaro Martín-Rivada,Mercedes Murray Hurtado,Elena Martín-Hernández

DOI: https://doi.org/10.3389/fnut.2024.1416466

2024-09-30

Abstract:Ornithine transcarbamylase deficiency (OTCD) is the most common disorder of the urea cycle and is caused by a mutation of the OTC gene, located on chromosome X. Its prevalence is estimated at 1 in 80,000 to 56,500 births, but this X-chromosomal inheritance results in males being more affected than females. In neonates affected with this disorder, hyperammonemia after birth can lead to neurological and liver damage that can be fatal. We present a child with a prenatal diagnosis based on an older sibling with the same pathology, which led us to adopt an intensive treatment since the delivery. He was admitted in a neonatal unit and treatment with protein restriction, 10% glucose saline serum and glycerol phenylbutyrate was initiated. To date, after 3.5 years of follow up, growth and neurological development have been adequate, biochemical control has been appropriate except for a simple and mild decompensation during the course of a gastroenteritis. This case emphasises the importance of early diagnosis and treatment to avoid potential complications.
Hyperammonemic Encephalopathy in a Child with Ornithine Transcarbamylase Deficiency Due to a Novel Combined Heterozygous Mutations

Jiandi Gao,Feng Gao,Fang Hong,Huimin Yu,Peifang Jiang

DOI: https://doi.org/10.1016/j.ajem.2014.08.038

2015-01-01

Abstract:Ornithine transcarbamylase deficiency (OTCD) is an X-linked disorder of metabolism of the urea cycle. It usually causes hyperammonemic encephalopathy in males during the neonatal-to-infantile period, whereas female carriers present with variable manifestations depending on their pattern of random chromosome X inactivation in the liver. Early clinical manifestations of hyperammonemia are nonspecific often leading to a delay in the diagnosis of OTCD. Unfortunately, delays in initiating treatment often lead to poor neurologic outcomes and overall survival. Presentation of hyperammonemic encephalopathy in children with OTCD is rare, and the mortality and morbidity rates are high. The diagnosis of OTCD and aggressive management of hyperammonemia were of paramount importance for appropriate treatment and successful recovery. Here, we report the clinical, biochemical, and molecular findings in a child with OTCD who presented with acute hyperammonemic encephalopathy.
Neonate-onset Ornithine Transcarbamylase Deficiency

Rui-Wei Gao,Yin Ba,Rong Zhang,Yun Cao,Lin Yang,Bing-Bing Wu,Wen-Hao Zhou,Jian-Guo Zhou

DOI: https://doi.org/10.7499/j.issn.1008-8830.2302023

2023-01-01

Abstract:The male neonate in this case study was admitted to the hospital at 15 hours of age due to respiratory distress for 15 hours and poor response for 3 hours after resuscitation from asphyxia. The neonate was highly unresponsive, with central respiratory failure and seizures. Serum ammonia was elevated (>1 000 μmol/L). Blood tandem mass spectrometry revealed a significant decrease in citrulline. Rapid familial whole genome sequencing revealed OTC gene mutations inherited from the mother. Continuous hemodialysis filtration and other treatments were given. Neurological assessment was performed by cranial magnetic resonance imaging and electroencephalogram. The neonate was diagnosed with ornithine transcarbamylase deficiency combined with brain injury. He died at 6 days of age after withdrawing care. This article focuses on the differential diagnosis of neonatal hyperammonemia and introduces the multidisciplinary management of inborn error of metabolism.
[Report of a case with late-onset ornithine transcarbamylase deficiency with gas chromatography-mass spectrometry and DNA sequencing confirmation and literatures review]

Wenjia Tong,Danqun Jin,Jingmin Sun

Abstract:Objective: To discuss the clinical characteristics, diagnosis and treatment management of ornithine transcarbamylase deficiency (OTCD). Method: Data of the clinical diagnosis and treatment of a case with OTCD were analyzed, and the domestic and international literature was reviewed. Result: (1) The case was a boy, 8 years old; and the initial symptoms were vomiting and reduced consciousness for a day after eating a lot of eggs as previous similar history. The level of blood ammonia was 2 500 µmol/L. The patient was treated with fasting, high-calorie fluid intravenous infusion, reducing blood ammonia. However, the disease further aggravated and the patient died due to brain hernia and central cardiovascular failure. Finally, he was confirmed as OTCD through urine testing by gas chromatography-mass spectrometry, plasma amino acid examination (plasma arginine and citrullineurine reduced, orotic acid raised) and genetic testing (OTC c.386G>A p. (Arg129His)). (2) Data of 55 case reports about diagnosis and treatment outcome including 65 OTCD cases' clinical data in domestic and abroad reports in nearly 5 years. Their ages ranged from 3 days to 49 years; the common symptoms were vomiting and encephalopathy; both urine tests were positive in 52 cases; pathogenic genes had less repeated loci and located at Xp21.1 in 42 cases detected by OTC gene test; all of which had gene mutation. Conclusion: The acute onset OTCD begins with the symptoms of vomiting and unconsciousness, with rapid rise of blood ammonia level. OTCD may cause high mortality.
Variable disease manifestations and metabolic management within a single family affected by ornithine transcarbamylase deficiency

Joshua Baker,Lauren Hitchins,Erika Vucko,Kirsten Havens,Karen Becker,Katherine Arduini

DOI: https://doi.org/10.1016/j.ymgmr.2022.100906

2022-07-30

Abstract:We report on a family with ornithine transcarbamylase (OTC) deficiency, an X-linked urea cycle disorder, with variable disease severity and tailored management strategies based on each family member's biochemical profile and clinical presentation. Our primary patient is a female monozygotic twin who presented to medical care at 10 months of age with acute liver failure, gastrointestinal symptoms, altered mental status, hypoglycemia, and hyperammonemia. The patient's older brother, known to have hemizygous OTC deficiency, died at 8 months of age from cardiac arrest after complications secondary to his diagnosis. Despite her family history, manifestation of symptoms of heterozygous (partial) OTC deficiency went unrecognized by multiple providers based on misconceptions regarding a female's risk for X-linked disease. Despite barriers related to the family's low socioeconomic status, follow-up care by a multidisciplinary metabolic care team, including moderate protein restriction and nitrogen scavenger therapy, led to positive outcomes for the patient. Her twin sister and mother are also heterozygous for variants in OTC and remain controlled on moderate protein restriction. This case illustrates the importance of genotyping all individuals with genetic risk factors for OTC deficiency and the variability in disease manifestation that necessitates tailored treatment approaches for individuals with partial OTC deficiency.
Analysis of clinical features, biochemical analysis and gene mutations in one Chinese pedigree with neonatal-onset ornithine transcarbamylase deficiency

Wei-hua SUN,Yi YANG,Yue-ping ZHANG,Xiao-tian LI,Min ZHANG,Yun CAO,Yi WANG

DOI: https://doi.org/10.3760/cma.j.issn.0578-1310.2011.05.009

2011-01-01

Abstract:Objective This study aimed at understanding clinical features, biochemistry and gene mutation in one Chinese pedigree which had a neonatal-onset ornithine transcarbamylase deficiency ( OTCD )boy, and exploring the significance of ornithine transcarbamylase analysis in prenatal diagnosis.Method The clinical and biochemical data of one case were analyzed.The amino acids in blood and organic acids in urine were analyzed by mass spectrum technology.The OTC gene mutation was detected using polymerase chain reaction (PCR) and DNA direct sequencing for the case, his parents and the fetus amniocyte and her blood after birth.Result The age of onset was 3 days after birth, he began to have poor reaction, difficulty to feed, high blood ammonia, infection, slight metabolic acidosis, which were consistent with the clinical diagnosis of urea cycle disorders.The boy died at the age of 9 days.Citrulline of blood was detected twice,and were 0.86 μm and 1.06 μm, respectively.The orotic acid was elevated ( 124 μm/M Creatinine), and urine lactic acid was significantly elevated.The citrulline and orotic acid in his parents and their second baby were normal in DBS and urine.One nonsense mutation in the OTC gene was found at the exon 9 ( C.958 C ＞ T) and his mother was the heterozygote, which caused an arginine to terminate the code at position 320 of the protein (R320X).Two other mutations were also detected at intron 9 ( C.1005 + 132 InsT) and intron 5 (C.542 + 134 G ＞ G/A).But the analysis of his father's DNA, the fetus amniocyte and her bloodwas normal.Conclusion The mutation of C.958 C ＞ T in OTC gene may occur during neonatal period.This mutation would result in a very severe symptom, even die suddenly several days after birth, if it was a boy.It needs more researches to discuss whether the C.1005 + 132 InsT in intron 9 and C.542 + 134 G ＞G/A in intron 5 were associated with the neonatal-onset OTCD.The DNA analysis of OTC gene could be utilized for the prenatal diagnosis.
Doing the B-cell rag. B cell development sponsored by the European Network of Immunology Institutes (ENII), Turku, Finland, June 8-9, 1991.

O. Lassila,O. Vainio,P. Toivanen,F. Melchers

1991-12-01

Abstract:
S4248 Recurrent Hepatic Encephalopathy in an Adult Without Chronic Liver Disease

Syed Mujtaba Baqir,Carla Barberan Parraga,Jimyeong Son,Tanuj Chokshi,James Park

DOI: https://doi.org/10.14309/01.ajg.0001046360.52303.8d

2024-10-26

The American Journal of Gastroenterology

Abstract:Ornithine transcarbamylase deficiency (OTCD) is the most prevalent inherited disorder of the urea cycle, commonly seen to have an X-linked recessive pattern. It is characterized by inability to metabolize and excrete ammonia leading to an increase in blood ammonia levels and significant neurologic sequele and mortality. Its incidence is known to be between 1 in 56,500 and 1 in 77000. We present a case of ornithine transcarbamylase deficiency, which initially presented as encephalopathy, with a suspicion of liver cirrhosis, however later cirrhosis was ruled out and the presentation was attributed to urea cycle disorder.

gastroenterology & hepatology
Selective upregulation of a functional β7 integrin on differentiating eosinophils

Joachim Lundahl,R. Sehmi,L. Hayes,K. Howie,J. Denburg

DOI: https://doi.org/10.1034/j.1398-9995.2000.00574.x

2000-09-01

Abstract:Background: The sequence of adhesion‐molecule expression during eosinophil differentiation remains unclear.
The After-Effects of Wounds of the Chest and their Treatment.

J. Meakins,T. Walker

1918-10-01

Canadian Medical Association Journal

Abstract:
Variant analysis and PGT-M of OTC gene in a Chinese family with ornithine carbamoyltransferase deficiency

Yao Zhou,Xinxing Jiang,Yongfang Zhang,Yu Zhang,Fei Sun,Yanlin Ma

DOI: https://doi.org/10.1186/s12884-024-06696-5

2024-07-22

Abstract:Background: Ornithine carbamoyltransferase deficiency (OTCD) is a kind of X-linked metabolic disease caused by a deficiency in ornithine transcarbamylase leading to urea cycle disorders. The main reason is that the OTC gene variants lead to the loss or decrease of OTC enzyme function, which hinders the ammonia conversion to urea, resulting in hyperammonemia and severe neurological dysfunction. Here, we studied one Chinese family of three generations who consecutively gave birth to two babies with OTCD. This study aims to explore the pathogenicity of two missense variants in the OTC gene and investigate the application of preimplantation genetic testing for monogenic (PGT-M) for a family troubled by Ornithine carbamoyltransferase deficiency (OTCD). Methods: The retrospective method was used to classify the pathogenicity of two missense variants in the OTC gene in a family tortured by OTCD. Sanger sequencing was used to validate the variants in the OTC gene, and then the pathogenicity of variants was confirmed through family analysis and bioinformatics software. We used PGT-M to target the OTC gene and select a suitable embryo for transplantation. Prenatal diagnosis was recommended to confirm previous results using Sanger sequencing and karyotyping at an appropriate gestational stage. Tandem mass spectrometry (MS-MS) and gas chromatography-mass spectrometry (GC-MS) were used to detect fetal metabolism after birth. The number of the study cohort is ChiCTR2100053616. Results: Two missense variants, c.959G > C (p.Arg320Pro) and c.634G > A (p.Gly212Arg), were validated in the OTC gene in this family. According to the ACMG genetic variation classification criteria, the missense variant c.959G > C can be considered as "pathogenic", and the missense variant c.634G > A can be regarded as "likely benign." PGT-M identified a female embryo carrying the heterozygous variant c.959G > C (p.Arg320Pro), which was selected for transplantation. Prenatal diagnosis revealed the same variant in the fetus, and continued pregnancy was recommended. A female baby was born, and her blood amino acid testing and urine organic acid testing were regular. Follow-up was conducted after six months and indicated the girl was healthy. Conclusion: Our research first validated the segregation of both c.959G > C and c.634G > A variants in the OTC gene in a Chinese OTCD family. Then, we classified variant c.959G > C as "pathogenic" and variant c.634G > A as "likely benign", providing corresponding theoretical support for genetic counseling and fertility guidance in this family. PGT-M and prenatal diagnosis were recommended to help the couple receive a female baby successfully with a six-month follow-up.
[Hypertrophy of the ileocecal valve. Malabsorption syndrome].

A. Salama,J. Albina

1969-04-25

Abstract:
Urinary Uracil: A Useful Marker for Ornithine Transcarbamylase Deficiency in Affected Males.

Hind Alsharhan,Hana Alharbi,Jessica Priestley,Rebecca Ganetzky,Miao He

DOI: https://doi.org/10.1093/clinchem/hvaa101

IF: 12.114

2020-01-01

Clinical Chemistry

Abstract:A previously healthy 12-month-old boy presented with recurrent episodes of emesis for a week after eating his birthday cake. He had multiple visits to the emergency department for poor feeding and sleepiness, where he received dextrose-containing intravenous fluids (IVF) with mild improvement. He was lethargic with normal vital signs. Plasma ammonia (NH3) was increased at 156 μmol/L (reference interval (RI): 9-33) and he was started on 10% dextrose-containing IVF at 1.5 maintenance rate, IV loading dose of nitrogen scavenger (NS), Ammonul (250 mg/Kg over 2 hr) followed with 24-hr infusion (250 mg/Kg/24 hr). Plasma glucose, total CO2 and anion gap were within reference intervals; while plasma hepatic enzymes, alanine aminotransferase (ALT) (64 U/L; RI: 10-30) and aspartate aminotransferase (AST) (83 U/L; RI: 20-60) were increased, and prothrombin time (PT) was prolonged at 17.7 seconds (s)(RI: 10.5 – 13.0). Plasma amino acids (PAA) revealed undetectable citrulline (<2 μmol/L) (RI: 7-47), increased glutamine (1,635 μmol/L) (RI: 285-832). Organic acids revealed increased urinary uracil (UU, 36 mg/g Cr)(RI:0-21) concerning for ornithine transcarbamylase deficiency (OTCD). Subsequently quantitative urine orotic acid (OA) was increased at 21.09 mmol/mol Cr (RI: 1.15-3.09) and OTC gene sequencing revealed a hemizygous pathogenic mutation: c.386G>A (p.Arg129His), previously reported in both neonatal and late-onset OTCD (1,2). He was managed with IVF,
[Rational lymphadenectomy in patients with cervical nodes metastasis for carcinoma of the lower third esophagus].

M. Baba,Y. Heiji,M. Shimada,S. Nakano,S. Natsugoe,T. Aikou

1997-09-01

Abstract:Prognostic value of removing cervical nodes in patients with carcinoma of the lower third esophagus is extremely controversial. Of 93 patients with curative esophagectomy via trans-thoracic approach, cervical nodes were involved in five patients (13%), upper mediastinal nodes in 12 patients (30%), and para-aortic nodes in only one patients (3%) for 40 patients whose proximal part of the tumor invading the mid-esophagus from below. Of the remaining 53 patients with tumor extent confined to the lower third esophagus, cervical nodes were involved in only one patients (2%), upper mediastinal nodes in five patients (9%), and paraaortic nodes in six patients (11%). Three of the five patients with cervical metastasis whose proximal part of the tumor invading the mid-esophagus survived for at least 22 months or more following three-field lymphadenectomy. Removing the cervical nodes in patients with carcinoma of the lower third esophagus may have some role to improve the survival if the tumor invades the mid-esophagus from below.
Clinical characteristics and molecular genetic analysis of ten cases of ornithine carbamoyltransferase deficiency in southeastern China

Gaopin Yuan,Zhiyong Liu,Zhixu Chen,Xiaohong Zhang,Weifeng Zhang,Dongmei Chen

DOI: https://doi.org/10.1186/s13052-024-01740-8

2024-09-11

Abstract:Background: This study aimed to investigate the clinical and molecular genetic characteristics of ten children with ornithine carbamoyltransferase deficiency (OTCD) in southeastern China, as well as the correlation between the genotype and phenotype of OTCD. Methods: A retrospective analysis was performed on the clinical manifestations, laboratory testing, and genetic test findings of ten children with OTCD admitted between August 2015 and October 2021 at Quanzhou Maternity and Children's Hospital of Fujian Province in China. Results: Five boys presented with early-onset symptoms, including poor appetite, drowsiness, groaning, seizures, and liver failure. In contrast, five patients (one boy and four girls) had late-onset gastrointestinal symptoms as the primary clinical manifestation, all presenting with hepatic impairment, and four with hepatic failure.Nine distinct variants of the OTC gene were identified, including two novel mutations: c.1033del(p.Y345Tfs*50) and c.167T > A(p.M56K). Of seven patients who died, five had early-onset disease despite active treatment. Three patients survived, and two of them underwent liver transplantation. Conclusions: The clinical manifestations of OTCD lack specificity. However, elevated blood ammonia levels serve as a crucial diagnostic clue for OTCD. Genetic testing aids in more accurate diagnosis and prognosis assessment by clinicians. In addition, we identified two novel pathogenic variants and expand the mutational spectrum of the gene OTC, which may contribute to a better understanding of the clinical and genetic characteristics of OTCD patients.
Benefits of tailored disease management in improving tremor, white matter hyperintensities, and liver enzymes in a child with heterozygous X-linked ornithine transcarbamylase deficiency

Ashley Andrews,Sarah Roberts,Lorenzo D Botto

DOI: https://doi.org/10.1016/j.ymgmr.2022.100891

2022-07-02

Abstract:We report the case of a 19-month-old girl with late-onset ornithine transcarbamylase (OTC) deficiency initially referred to gastroenterology for intermittent vomiting lasting a year and abnormal liver enzymes (AST 730 U/L [reference range 26-55 U/L]; ALT 1213 U/L [reference range 11-30 U/L]) without hepatomegaly. While the patient was hospitalized for liver biopsy, intermittent tremors of the upper extremities with varying severity were noted. The patient was presumed to have hyperammonemia secondary to acute liver failure and was discharged after 5 days; follow-up monitoring led to readmission 7 days later. A brain MRI showed nonspecific bilateral pericallosal and bifrontal white matter FLAIR hyperintensities. These findings raised suspicion for a metabolic disease and prompted a genetics consultation. After inconclusive biochemical testing and worsening clinical status, rapid whole genome sequencing results were obtained identifying a novel, de novo, likely pathogenic, variant c.608C > T (p.Ser203Phe) in the OTC gene. The patient was promptly started on an oral nitrogen scavenger, citrulline supplementation, and protein restriction. Ammonia and glutamine levels normalized within 1 month of treatment and have stayed within the goal ranges with continued tailoring of treatment. Her parents noted resolution of vomiting and improved mood stability. Liver enzymes normalized after 2 months of treatment. The tremor, identified as asterixis, improved and a repeat brain MRI 3 months after the initial imaging showed near-complete resolution of previous white matter hyperintensities.
THE ARGENTINE CITIZENS DECLARATION.

P. Bard,C. Best,H. Davis,H. Essex,W. O. Fenn,W. F. Hamilton,M. Visscher

DOI: https://doi.org/10.1126/SCIENCE.99.2565.166

IF: 56.9

1944-02-25

Science

Abstract:
Long-term Follow-Up of Children with Carbamoyl Phosphate Synthase 1 Deficiency Detected in Newborn Screening.

Zhanming Zhang,Fan Tong,Chi Chen,Ting Zhang,Guling Qian,Xin Yang,Xinwen Huang,Rulai Yang,Zhengyan Zhao

DOI: https://doi.org/10.3724/zdxbyxb-2023-0359

2023-01-01

Abstract:OBJECTIVES:To investigate genotype-phenotype characteristics and long-term prognosis of neonatal carbamoyl phosphate synthetase 1 (CPS1) deficiency among children through newborn screening in Zhejiang province.METHODS:The clinical and follow-up data of children with CPS1 deficiency detected through neonatal screening and confirmed by tandem mass spectrometry and genetic testing in Zhejiang Province Newborn Disease Screening Center from September 2013 to August 2023 were retrospectively analyzed.RESULTS:A total of 4 056 755 newborns were screened and 6 cases of CPS1 deficiency were diagnosed through phenotypic and genetic testing. Ten different variations of CPS1 genewere identified in genetic testing, including 2 known pathogenic variations (c.2359C>T and c.1549+1G>T) and 8 unreported variations (c.3405-1G>T, c.2372C>T, c.1436C>T, c.2228T>C, c.2441G>A, c.3031G>A, c.3075T>C and c.390-403del). All patients had decreased citrulline levels (2.72-6.21 μmol/L), and varying degrees of elevated blood ammonia. The patients received restricted natural protein intake (special formula), arginine and supportive therapy after diagnosis, and were followed-up for a period ranging from 9 months to 10 years. Three patients experienced hyperammonemia, and one patient each had attention deficit hyperactivity disorder, transient facial twitching and increased muscle tone. One patient died, while the other five surviving patients had normal scores of the Ages & Stages Questionnaires (ASQ) and Griffiths Development Scales up to the present time; 4 cases had combined height or weight lag and one case was normal in height and weight.CONCLUSIONS:Low citrulline levels and hyperammonemia are common in CPS1 deficiency patients in Zhejiang. Most gene variants identified were specific to individual families, and no hotspot mutations were found. Early diagnosis through newborn screening and following standardized treatment can significantly improve the prognosis of the patients.
Two pregnancies of an ornithine carbamoyltransferase deficiency disease carrier and review of the literature

Loredana Arhip,Javier Agreda,Clara Serrano-Moreno,Marta Motilla de la Cámara,María Luisa Carrascal Fabián,Atocha Bielza,Cristina Velasco Gimeno,Miguel Camblor,Irene Bretón,Cristina Cuerda

DOI: https://doi.org/10.20960/nh.04867

2024-01-01

Nutrición Hospitalaria

Abstract:BACKGROUND: the underlying cause of the deficiency of ornithine carbamoyltransferase (OTCD) is a gene mutation on the X chromosome. In females, the phenotype is highly variable, ranging from asymptomatic to neurologic compromise secondary to hyperammonemia and it can be prompted by numerous triggers, including pregnancy.OBJECTIVE: the objective of this article is to report a case of two pregnancies of an OTCD-carrier, and to review the literature describing OTCD and pregnancy, parturition and postpartum.METHODS: an extensive search in PubMed in December 2021 was conducted using different search terms. After screening all abstracts, 23 papers that corresponded to our inclusion criteria were identified.RESULTS: the article focuses on the management of OTCD during pregnancy, parturition, and the postpartum period in terms of clinical presentation, ammonia levels and treatment.CONCLUSIONS: females with OTCD can certainly plan a pregnancy, but they need a careful management during delivery and particularly during the immediate postpartum period. If possible, a multidisciplinary team of physicians, dietitians, obstetrician-gynecologist, neonatologists, pharmacists, etc. with expertise in this field should participate in the care of women with OTCD and their children during this period and in their adult life.

nutrition & dietetics

Tubular epithelial reflux in the kidney in aflatoxin poisoning.

Newborn Screening for Ornithine Transcarbamylase Deficiency in Zhejiang Province and the Follow-Up Analysis

Perinatal management and follow-up in a child with a prenatal diagnosis of OTC deficiency: a case report

Hyperammonemic Encephalopathy in a Child with Ornithine Transcarbamylase Deficiency Due to a Novel Combined Heterozygous Mutations

Neonate-onset Ornithine Transcarbamylase Deficiency

[Report of a case with late-onset ornithine transcarbamylase deficiency with gas chromatography-mass spectrometry and DNA sequencing confirmation and literatures review]

Variable disease manifestations and metabolic management within a single family affected by ornithine transcarbamylase deficiency

Analysis of clinical features, biochemical analysis and gene mutations in one Chinese pedigree with neonatal-onset ornithine transcarbamylase deficiency

Doing the B-cell rag. B cell development sponsored by the European Network of Immunology Institutes (ENII), Turku, Finland, June 8-9, 1991.

S4248 Recurrent Hepatic Encephalopathy in an Adult Without Chronic Liver Disease

Selective upregulation of a functional β7 integrin on differentiating eosinophils

The After-Effects of Wounds of the Chest and their Treatment.

Variant analysis and PGT-M of OTC gene in a Chinese family with ornithine carbamoyltransferase deficiency

[Hypertrophy of the ileocecal valve. Malabsorption syndrome].

Urinary Uracil: A Useful Marker for Ornithine Transcarbamylase Deficiency in Affected Males.

[Rational lymphadenectomy in patients with cervical nodes metastasis for carcinoma of the lower third esophagus].

Clinical characteristics and molecular genetic analysis of ten cases of ornithine carbamoyltransferase deficiency in southeastern China

Benefits of tailored disease management in improving tremor, white matter hyperintensities, and liver enzymes in a child with heterozygous X-linked ornithine transcarbamylase deficiency

THE ARGENTINE CITIZENS DECLARATION.

Long-term Follow-Up of Children with Carbamoyl Phosphate Synthase 1 Deficiency Detected in Newborn Screening.

Two pregnancies of an ornithine carbamoyltransferase deficiency disease carrier and review of the literature